Now Available! | Check out UMR’s 2024 Annual Economic Report and State Toolkits today
NIH Research 101 | UMR Answers Common Questions About NIH Research in this New Fact Sheet Series
Rural State Analysis | UMR's 2023 Report Reveals the Exponential Impact of NIH Research Funding in 7 Rural States
Why Invest in NIH Research? | UMR Offers Fact Sheets Explaining Why Congress Must #keepNIHstrong

A participant in the NIH 2019-2020 Medical Research Scholars Program.

Photo Credit: National Institutes of Health

About This Photo

Turning the Tide on Ebola: A Conversation with NIAID’s Dr. Anthony Fauci & Regeneron’s Neil Stahl


NIAID’s Dr. Anthony Fauci
Regeneron Executive Vice President for Research and Development, Neil Stahl

In this episode of the Amazing Things Podcast, we talk to Dr. Anthony Fauci, director of NIH’s National Institute of Allergies and Infectious Diseases and Regeneron Pharmaceutical Executive Vice President for Research and Development Neil Stahl and how their organizations supported the effort to develop effective treatments for Ebola.

A major outbreak of the Ebola virus in West Africa from 2014–2016 infected tens of thousands and captured worldwide attention as it traveled across borders and even made its way to the United States. While rare, Ebola is particularly frightening as it has eluded effective treatment since it first appeared in 1976. Approximately half of those who contract it will die.


However, in August 2019, a multinational effort — spearheaded by the World Health Organization, the National Institutes of Health (NIH) and the Institut National de Recherche Biomédicale — turned the tide on Ebola. Critical to this effort was the research and drug development efforts of private sector companies and the NIH.